<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02889523</url>
  </required_header>
  <id_info>
    <org_study_id>Epi-RCHOP</org_study_id>
    <nct_id>NCT02889523</nct_id>
  </id_info>
  <brief_title>Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy</brief_title>
  <acronym>Epi-RCHOP</acronym>
  <official_title>A Phase Ib-II Study of Tazemetostat (EPZ-6438) in Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL) or High Risk Follicular Lymphoma (FL) Patients Treated by R-CHOP</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Lymphoma Academic Research Organisation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Epizyme, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Lymphoma Academic Research Organisation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I of the study is designed to determine the recommended phase II dose (RP2D) for&#xD;
      tazemetostat in patients treated with 8 cycles of R-CHOP 21.&#xD;
&#xD;
      Phase II of the study is designed to determine the safety and the efficacy of tazemetostat in&#xD;
      DLBCL and FL patients :&#xD;
&#xD;
      DLBCL : tazemetostat with 6 cycles of R-CHOP 21 + 2 cycles of Rituximab FL : tazemetostat&#xD;
      with 6 cycles of R-CHOP 21 + 2 cycles of Rituximab then maintenance with 6 months of&#xD;
      tazemetostat and 24 months of Rituximab&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase I:&#xD;
&#xD;
      Up to 18 patients will be recruited, using a conventional dose-escalation algorithm (3+3&#xD;
      patients per dose level) to identify the maximum tolerated dose (MTD) which will be deemed&#xD;
      the RP2D. Patients will receive 8 cycles of RCHOP every 21 days and tazemetostat every day,&#xD;
      starting on day 2 of cycle 1.&#xD;
&#xD;
      4 cohorts are defined, according to dose levels of tazemetostat: 400mg Twice a day (BID)&#xD;
      (cohort 1, starting level), 600mg BID (cohort 2), 800mg BID (cohort 3), 200mg BID (cohort&#xD;
      -1), depending on the observed toxicities.&#xD;
&#xD;
      Phase II:&#xD;
&#xD;
      Up to 184 patients (122 DLBCL and 62 FL) will be recruited and treated with tazemetostat at&#xD;
      the MTD and RCHOP.&#xD;
&#xD;
      Patients will receive 6 cycles of RCHOP every 21 days and tazemetostat at the MTD every day,&#xD;
      starting on day 2 of cyle 1, + 2 cycles of Rituximab+tazemetostat. For FL, a maintenance of&#xD;
      tazemetostat (6 months) + rituximab (24 months) is expected&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Anticipated">April 2026</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I : Number of Dose Limiting Toxicities</measure>
    <time_frame>1 cycle (1 cycle is 21 days)</time_frame>
    <description>Incidence and severity of treatment-emergent AEs qualifying as protocol defined DLT's in cycle 1 and 2 in order to establish the MTD/RP2D</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase I : Number of Dose Limiting Toxicities</measure>
    <time_frame>2 cycles (1 cycle is 21 days)</time_frame>
    <description>Incidence and severity of treatment-emergent AEs qualifying as protocol defined DLT's in cycle 1 and 2 in order to establish the MTD/RP2D</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II - DLBCL Cohort : Complete Response Rate based on local assessment</measure>
    <time_frame>8 cycles (1 cycle is 21 days)</time_frame>
    <description>Complete response rate as determined by Cheson International Work Group (IWG) 2014: Lugano Classification (Deauville scale 1-3)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II - FL Cohort : Complete Response Rate based on local assessment</measure>
    <time_frame>8 cycles (1 cycle is 21 days)</time_frame>
    <description>Complete response rate as determined by Cheson IWG 2014: Lugano Classification (Deauville scale 1-3)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase I : Serum concentration of CHOP components in presence/absence of Tazemetostat</measure>
    <time_frame>Change between baseline - 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I : Serum concentration of Tazemetostat and its metabolite (EZH 6930) in presence of CHOP</measure>
    <time_frame>Change between baseline - 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I : Complete response rate (CRR) by central review using Cheson IWG criteria</measure>
    <time_frame>8 cycles (1 cycle is 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II - DLBCL Cohort : Number of Adverse Events (AE)/Serious Adverse Events (SAE)</measure>
    <time_frame>8 cycles (1 cycle is 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II - DLBCL Cohort : Complete response rate (CRR) by central review using Cheson IWG criteria</measure>
    <time_frame>8 cycles (1 cycle is 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II - DLBCL Cohort : Overall response rate (ORR) by central review</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II - DLBCL Cohort : Overall response rate (ORR) by central review</measure>
    <time_frame>104 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II - DLBCL Cohort : progression free survival (PFS)</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II - DLBCL Cohort : progression free survival (PFS)</measure>
    <time_frame>104 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II - DLBCL Cohort : duration of response (DR)</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II - DLBCL Cohort : duration of response (DR)</measure>
    <time_frame>104 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II - DLBCL Cohort : overall survival (OS)</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II - DLBCL Cohort : overall survival (OS)</measure>
    <time_frame>104 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II - DLBCL Cohort : best overall response (BOR)</measure>
    <time_frame>104 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II - FL cohort : Number of AE/SAE</measure>
    <time_frame>8 cycles (1 cycle is 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II - FL cohort : Number of AE/SAE</measure>
    <time_frame>13 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II - FL cohort : PET Complete Response Rate (PET-CRR) by central review according to Lugano 2014 criteria</measure>
    <time_frame>8 cycles (1 cycle is 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II - FL cohort : Complete Response Rate (CRR)</measure>
    <time_frame>31 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II - FL cohort : Overall Response Rate (CRR)</measure>
    <time_frame>31 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II - FL cohort : Progression Free Survival (PFS)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II - FL cohort : Progression Free Survival (PFS)</measure>
    <time_frame>31 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II - FL cohort : Event Free Survival (EFS)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II - FL cohort : Overall Survival (OS)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II - FL cohort : Duration of Response (DR)</measure>
    <time_frame>31 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II - FL cohort : Best Overall Response</measure>
    <time_frame>31 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">201</enrollment>
  <condition>Lymphoma</condition>
  <condition>DLBCL</condition>
  <condition>Follicular Lymphoma</condition>
  <arm_group>
    <arm_group_label>DLBCL cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RCHOP + tazemetostat:&#xD;
- RCHOP: rituximab (IV, 375 mg/m², day 1), Prednisolone (PO, 40 mg/m² in the morning, day 1 to day 5), doxorubicine (IV, 50 mg/m², day 1), cyclophosphamide (IV, 750 mg/m², day 1), vincristine (IV, 1.4 mg/m², day 1): Phase I : 8 cycles, every 21 days Phase II : 6 cycles, every 21 days&#xD;
Rituximab (IV, 375 mg/m², day 1) Phase II : 2 cycles, every 21 days&#xD;
Tazemetostat: PO, doses according to dose cohorts for phase I, and at RP2D for phase II: continuous: Cycle 1: 2 to 21 BID, Cycle 2-8: 1 to 21 BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FL cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RCHOP + tazemetostat:&#xD;
Induction&#xD;
RCHOP: rituximab (IV, 375 mg/m², day 1), Prednisolone (PO, 40 mg/m² in the morning, day 1 to day 5), doxorubicine (IV, 50 mg/m², day 1), cyclophosphamide (IV, 750 mg/m², day 1), vincristine (IV, 1.4 mg/m², day 1):&#xD;
6 cycles, every 21 days&#xD;
Rituximab (IV, 375 mg/m², day 1) Phase II : 2 cycles, every 21 days&#xD;
Tazemetostat: PO, RP2D, continuous: Cycle 1: 2 to 21 BID, Cycle 2-8: 1 to 21 BID&#xD;
Maintenance&#xD;
Tazemetostat : 6 months (every 8 weeks)&#xD;
Rituximab : 24 months (every 8 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tazemetostat</intervention_name>
    <description>Tablets 200 mg, to be administrated per os</description>
    <arm_group_label>DLBCL cohort</arm_group_label>
    <arm_group_label>FL cohort</arm_group_label>
    <other_name>EPZ-6438</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>375 mg/m²/dose, D1</description>
    <arm_group_label>DLBCL cohort</arm_group_label>
    <arm_group_label>FL cohort</arm_group_label>
    <other_name>Mabthera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>750 mg/m²/dose, D1</description>
    <arm_group_label>DLBCL cohort</arm_group_label>
    <arm_group_label>FL cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>1.4 mg/m²/dose (max 2 mg), D1</description>
    <arm_group_label>DLBCL cohort</arm_group_label>
    <arm_group_label>FL cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>50 mg/m²/dose, D1</description>
    <arm_group_label>DLBCL cohort</arm_group_label>
    <arm_group_label>FL cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>40 mg/m2 in the morning D1 to D5</description>
    <arm_group_label>DLBCL cohort</arm_group_label>
    <arm_group_label>FL cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA&#xD;
&#xD;
               -  for Cohort DLBCL ONLY&#xD;
&#xD;
                    -  1-Patients with an untreated DLBCL de novo or transformed from indolent&#xD;
                       lymphoma (CD 20 positive) with&#xD;
&#xD;
                         -  Phase Ib aaIPI ≥ 2&#xD;
&#xD;
                         -  Phase II: aaIPI ≥ 1ONLY&#xD;
&#xD;
                    -  2. Age between 60 and 80 years included&#xD;
&#xD;
               -  for Cohort FOLLICULAR ONLY&#xD;
&#xD;
                    -  1-High Tumor Burden (as defined by GELF criteria &gt; 0) frontline follicular&#xD;
                       lymphoma (FL) with high risk FLIPI 3-5&#xD;
&#xD;
                    -  2. Aged between 18 years and 80 years included&#xD;
&#xD;
                    -  11bis. Females of childbearing potential (FCBP) must agree to use one&#xD;
                       reliable form of contraception or to practice complete abstinence from&#xD;
                       heterosexual contact during the following time periods related to this&#xD;
                       study: 1) for at least 28 days before starting study drug; 2) while&#xD;
                       participating in the study; 3) dose interruptions; and 4) for at least 12&#xD;
                       months after discontinuation of any study treatments (R-CHOP, tazemetostat,&#xD;
                       Rituximab)&#xD;
&#xD;
               -  For both Cohorts&#xD;
&#xD;
                    -  1bis- For phase II patients: Bi-dimensionally measurable disease defined by&#xD;
                       at least one single node or tumor lesion &gt; 1.5 cm assessed by CT scan and/or&#xD;
                       clinical examination AND a FDG avid disease by PETscan&#xD;
&#xD;
                    -  3.ECOG performance status of 0, 1 or 2 (0 or 1 only for phase Ib)&#xD;
&#xD;
                    -  4.Signed informed consent&#xD;
&#xD;
                    -  5.Life expectancy of ≥ 90 days (3 months) before starting tazemetostat&#xD;
&#xD;
                    -  6.Adequate renal function as calculated by a creatinine clearance &gt; 40&#xD;
                       mL/min by local institutional formula&#xD;
&#xD;
                    -  7. Adequate bone marrow function as defined as:&#xD;
&#xD;
                         -  ANC ≥ 1500/mm3 (≥ 1.5 X 109/L)&#xD;
&#xD;
                         -  Platelets ≥ 75,000/mm3 (≥ 75 X 109/L) without platelet transfusion&#xD;
                            dependency during the last 7 days&#xD;
&#xD;
                         -  Hemoglobin ≥ 9 g/dL (may receive transfusion)&#xD;
&#xD;
                    -  8. Adequate liver function as defined as:&#xD;
&#xD;
                         -  Total bilirubin ≤ 1.5 × the upper limit of normal (ULN) except for&#xD;
                            unconjugated hyperbilirubinemia of Gilbert's syndrome&#xD;
&#xD;
                         -  Alkaline phosphatase (in absence of bone disease), alanine&#xD;
                            aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 X ULN&#xD;
                            (or ≤ 5 X ULN if related to lymphoma involvement)&#xD;
&#xD;
                         -  Patients with prior Hepatitis B and C are eligible if, for Hepatitis B&#xD;
                            detection, surface antigen is negative and/or HBV DNA is undetectable,&#xD;
                            and for Hepatitis C detection, if HCV RNA is undetectable.&#xD;
&#xD;
                    -  9. Left ventricular ejection fraction (LVEF) ≥ 50% of echocardiography or&#xD;
                       multiple gated acquisition (MUGA) scan&#xD;
&#xD;
                    -  10. Adequate tissue (surgical excision is recommended) for central pathology&#xD;
                       review and biological caracterisation (see appendix 11&#xD;
&#xD;
                    -  11. Males with partners of childbearing potential must agree to use reliable&#xD;
                       forms of contraception during 12 months after last treatment administration&#xD;
&#xD;
                    -  12. Patient covered by any social security system (for France only)&#xD;
&#xD;
                    -  13. Patient who understands and speaks one of the country official languages&#xD;
&#xD;
          -  EXCLUSION CRITERIA&#xD;
&#xD;
               -  for Cohort DLBCL&#xD;
&#xD;
                  ___15-Previous treatment for B cell lymphoma, except glucocorticoids (no more&#xD;
                  than 7 days before inclusion, 1 mg/kg/day max)&#xD;
&#xD;
               -  for Cohort FOLLICULAR ONLY&#xD;
&#xD;
                    -  14bis. Prior therapy for lymphoma including radiotherapy except&#xD;
                       glucocorticoids (no more than 7 days before inclusion, 1 mg/kg/day max)&#xD;
&#xD;
                    -  17-Pregnant or lactating females&#xD;
&#xD;
               -  For both Cohorts&#xD;
&#xD;
                    -  1-Central nervous system or meningeal involvement&#xD;
&#xD;
                    -  2-Contraindication to any drug contained in the chemotherapy regimen&#xD;
&#xD;
                    -  3-Prior treatment with tazemetostat or other inhibitor of EZH2&#xD;
&#xD;
                    -  4-Patients who are undergoing active treatment for another malignancy,&#xD;
                       exceptions include: A patient who has been disease free for 2 years, or a&#xD;
                       patient with a history of a completely resected non-melanoma skin cancer or&#xD;
                       successfully treated in situ carcinoma is eligible Patients with prior&#xD;
                       history of myeloid malignancies, including myelodysplastic syndrome (MDS) or&#xD;
                       Acute Myeloid Leukemia(AML) or prior history of T-LBL/T-ALL are excluded&#xD;
                       whatever receiving treatment or not and whatever date of diagnosis of these&#xD;
                       pathologies&#xD;
&#xD;
                    -  5-Patients taking medications that are known potent CYP3A4&#xD;
                       inducers/inhibitors (including St. John's wort)&#xD;
&#xD;
                    -  6-Patients unwilling to exclude St. John's wort, Seville oranges, grapefruit&#xD;
                       juice and/or grapefruit from diet&#xD;
&#xD;
                    -  7-Major surgery within 4 weeks before first dose of study drug (minor&#xD;
                       procedures including transcutaneous biopsy, central line placement are&#xD;
                       permitted within 2 weeks of enrollment)&#xD;
&#xD;
                    -  8-Inability to take oral medication or malabsorption syndrome or any other&#xD;
                       uncontrolled gastrointestinal condition that would impare ability to take&#xD;
                       tazemetostat&#xD;
&#xD;
                    -  9-Significant cardiovascular impairment: congestive heart failure greater&#xD;
                       than New York Heart Association (NYHA) Class II, unstable angina, myocardial&#xD;
                       infarction or stroke within 6 months of first dose of tazemetostat or&#xD;
                       ventricular arrhythmia&#xD;
&#xD;
                    -  10-Not applicable&#xD;
&#xD;
                    -  11-Active uncontrolled infection requiring systemic therapy&#xD;
&#xD;
                    -  12-Congenital immunodeficiency or known HIV (human immunodeficiency virus&#xD;
                       infection)&#xD;
&#xD;
                    -  13-Any other major illness, that in the investigator's judgement, will&#xD;
                       substantially increase the risk associated with the patient's participation&#xD;
                       in the study&#xD;
&#xD;
                    -  14-Patients who have undergone a solid organ transplant&#xD;
&#xD;
                    -  16-Treatment with any investigational drug or device within 30 days before&#xD;
                       planned first cycle of chemotherapy&#xD;
&#xD;
                    -  18-Person deprived of his/her liberty by a judicial or administrative&#xD;
                       decision&#xD;
&#xD;
                    -  19-Adult person under legal protection&#xD;
&#xD;
                    -  20-Person hospitalized without consent&#xD;
&#xD;
                    -  21-Adult person unabled to provide informed consent because of intellectual&#xD;
                       impairment, any serious medical condition, laboratory abnormality or&#xD;
                       psychiatric illness&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent Ribrag, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Gustave Roussy Cancer Campus Grand Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Clémentine Sarkozy, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Gustave Roussy Cancer Campus Grand Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Franck Morshhauser, Pr</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Régional Hospitalier de Lille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Loic Ysebaert, MD</last_name>
    <role>Study Chair</role>
    <affiliation>IUCT Oncopole de Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chloe Gourc-Berthod</last_name>
    <phone>+33 (04) 72 66 93 33</phone>
    <email>chloe.gourc-berthod@lysarc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie MAEREVOET, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Liege</name>
      <address>
        <city>Liege</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe BONNET, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Mont Godinne</name>
      <address>
        <city>Yvoir</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc ANDRE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Victor Dupouy</name>
      <address>
        <city>Argenteuil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Driss CHAOUI, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH d'Avignon - Hôpital Henri Dufaut</name>
      <address>
        <city>Avignon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hacene ZERAZHI, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Besançon - Hôpital Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marian HECZHO, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Polyclinique Bordeaux Nord Aquitaine</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Olivier FITOUSSI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Chambéry</name>
      <address>
        <city>Chambéry</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gian Matteo PICA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU d'Estaing</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Romain Guieze, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>APHP - Hopital Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corinne HAIOUN, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier CASASNOVAS, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Remy GRESSIN, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Départemental de Vendée</name>
      <address>
        <city>La Roche sur Yon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hervé MAISONNEUVE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Lille - Hôpital Claude Huriez</name>
      <address>
        <city>Lille Cedex</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franck MORSCHHAUSER, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu de Limoges - Hopital Dupuytren</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie ABRAHAM, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuelle NICOLAS-VIRELIZIER, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmette</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Marc SCHIANO DE COLLELA, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier - Hôpital Saint-Eloi</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume CARTRON, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes - Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven LE GOUILL, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital Saint Louis</name>
      <address>
        <city>Paris Cedex 10</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Thieblemont, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital de la Pitié Salpetrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvain Choquet, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de Perpigan</name>
      <address>
        <city>Perpignan</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Serrier, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Lyon Sud</name>
      <address>
        <city>Pierre-Bénite Cedex</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel BACHY, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu de Poitiers - Hopital de Miletrie</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent DELWAIL, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes - Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry LAMY-DE-LA-CHAPELLE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hervé TILLY, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Rene Hugenin</name>
      <address>
        <city>Saint Cloud</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvie GLAISNER, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de cancérologie de la Loire</name>
      <address>
        <city>Saint Priest en Jarez</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fressia HONEYMAN, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luc-Matthieu Fornecker, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer de Toulouse - Oncopole</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Loïc YSEBAERT, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent RIBRAG, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 11, 2016</study_first_submitted>
  <study_first_submitted_qc>August 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2016</study_first_posted>
  <last_update_submitted>July 23, 2021</last_update_submitted>
  <last_update_submitted_qc>July 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Front line therapy</keyword>
  <keyword>Age-adjusted International Prognostic Index (aa-IPI) &gt;1</keyword>
  <keyword>60 to 80 years</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

